Novartis (NVS) Competitors

Novartis logo
$160.02 -0.48 (-0.30%)
Closing price 11/16/2026 03:59 PM Eastern
Extended Trading
$160.78 +0.75 (+0.47%)
As of 04:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NVS vs. JNJ, MRK, AZN, NVO, and PFE

Should you buy Novartis stock or one of its competitors? Novartis's main competitors and comparable companies include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), AstraZeneca (AZN), Novo Nordisk A/S (NVO), and Pfizer (PFE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Novartis compare to Johnson & Johnson?

Johnson & Johnson (NYSE:JNJ) and Novartis (NYSE:NVS) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

In the previous week, Johnson & Johnson had 48 more articles in the media than Novartis. MarketBeat recorded 68 mentions for Johnson & Johnson and 20 mentions for Novartis. Johnson & Johnson's average media sentiment score of 0.84 beat Novartis' score of 0.52 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Johnson & Johnson
32 Very Positive mention(s)
16 Positive mention(s)
12 Neutral mention(s)
3 Negative mention(s)
4 Very Negative mention(s)
Positive
Novartis
4 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Johnson & Johnson has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market. Comparatively, Novartis has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market.

Johnson & Johnson presently has a consensus target price of $275.92, suggesting a potential downside of 2.37%. Novartis has a consensus target price of $152.25, suggesting a potential downside of 4.86%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, research analysts plainly believe Johnson & Johnson is more favorable than Novartis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Johnson & Johnson
0 Sell rating(s)
8 Hold rating(s)
17 Buy rating(s)
1 Strong Buy rating(s)
2.73
Novartis
3 Sell rating(s)
9 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.17

Johnson & Johnson has higher revenue and earnings than Novartis. Novartis is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Johnson & Johnson$94.19B7.22$26.80B$6.6042.82
Novartis$54.53B5.60$13.98B$5.2430.54

Novartis has a net margin of 18.11% compared to Johnson & Johnson's net margin of 16.20%. Novartis' return on equity of 41.04% beat Johnson & Johnson's return on equity.

Company Net Margins Return on Equity Return on Assets
Johnson & Johnson16.20% 31.64% 13.04%
Novartis 18.11%41.04%14.45%

Johnson & Johnson pays an annual dividend of $5.36 per share and has a dividend yield of 1.9%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 1.9%. Johnson & Johnson pays out 81.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novartis pays out 58.8% of its earnings in the form of a dividend. Johnson & Johnson has raised its dividend for 64 consecutive years. Novartis is clearly the better dividend stock, given its higher yield and lower payout ratio.

69.6% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 13.1% of Novartis shares are owned by institutional investors. 0.2% of Johnson & Johnson shares are owned by company insiders. Comparatively, 0.0% of Novartis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Johnson & Johnson beats Novartis on 14 of the 20 factors compared between the two stocks.

How does Novartis compare to Merck & Co., Inc.?

Novartis (NYSE:NVS) and Merck & Co., Inc. (NYSE:MRK) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

13.1% of Novartis shares are held by institutional investors. Comparatively, 76.1% of Merck & Co., Inc. shares are held by institutional investors. 0.0% of Novartis shares are held by company insiders. Comparatively, 0.2% of Merck & Co., Inc. shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Novartis has a net margin of 18.11% compared to Merck & Co., Inc.'s net margin of 3.64%. Novartis' return on equity of 41.04% beat Merck & Co., Inc.'s return on equity.

Company Net Margins Return on Equity Return on Assets
Novartis18.11% 41.04% 14.45%
Merck & Co., Inc. 3.64%16.73%5.88%

Novartis has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market. Comparatively, Merck & Co., Inc. has a beta of 0.13, indicating that its stock price is 87% less volatile than the broader market.

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 1.9%. Merck & Co., Inc. pays an annual dividend of $3.40 per share and has a dividend yield of 2.4%. Novartis pays out 58.8% of its earnings in the form of a dividend. Merck & Co., Inc. pays out 350.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Merck & Co., Inc. has increased its dividend for 14 consecutive years. Merck & Co., Inc. is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Novartis presently has a consensus price target of $152.25, suggesting a potential downside of 4.86%. Merck & Co., Inc. has a consensus price target of $155.74, suggesting a potential upside of 7.79%. Given Merck & Co., Inc.'s stronger consensus rating and higher possible upside, analysts clearly believe Merck & Co., Inc. is more favorable than Novartis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novartis
3 Sell rating(s)
9 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.17
Merck & Co., Inc.
1 Sell rating(s)
11 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
2.59

Merck & Co., Inc. has higher revenue and earnings than Novartis. Novartis is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novartis$54.53B5.60$13.98B$5.2430.54
Merck & Co., Inc.$65.01B5.48$18.25B$0.97148.96

In the previous week, Merck & Co., Inc. had 14 more articles in the media than Novartis. MarketBeat recorded 34 mentions for Merck & Co., Inc. and 20 mentions for Novartis. Merck & Co., Inc.'s average media sentiment score of 0.85 beat Novartis' score of 0.52 indicating that Merck & Co., Inc. is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novartis
4 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Merck & Co., Inc.
23 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
4 Negative mention(s)
2 Very Negative mention(s)
Positive

Summary

Merck & Co., Inc. beats Novartis on 13 of the 20 factors compared between the two stocks.

How does Novartis compare to AstraZeneca?

Novartis (NYSE:NVS) and AstraZeneca (NYSE:AZN) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

Novartis has higher earnings, but lower revenue than AstraZeneca. AstraZeneca is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novartis$54.53B5.60$13.98B$5.2430.54
AstraZeneca$58.74B4.86$10.23B$7.0726.02

In the previous week, AstraZeneca had 5 more articles in the media than Novartis. MarketBeat recorded 25 mentions for AstraZeneca and 20 mentions for Novartis. AstraZeneca's average media sentiment score of 0.74 beat Novartis' score of 0.52 indicating that AstraZeneca is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novartis
4 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
AstraZeneca
14 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
5 Negative mention(s)
0 Very Negative mention(s)
Positive

Novartis has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market. Comparatively, AstraZeneca has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

Novartis currently has a consensus target price of $152.25, suggesting a potential downside of 4.86%. AstraZeneca has a consensus target price of $206.67, suggesting a potential upside of 12.34%. Given AstraZeneca's stronger consensus rating and higher probable upside, analysts plainly believe AstraZeneca is more favorable than Novartis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novartis
3 Sell rating(s)
9 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.17
AstraZeneca
0 Sell rating(s)
3 Hold rating(s)
16 Buy rating(s)
0 Strong Buy rating(s)
2.84

13.1% of Novartis shares are owned by institutional investors. Comparatively, 20.4% of AstraZeneca shares are owned by institutional investors. 0.0% of Novartis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Novartis has a net margin of 18.11% compared to AstraZeneca's net margin of 17.68%. Novartis' return on equity of 41.04% beat AstraZeneca's return on equity.

Company Net Margins Return on Equity Return on Assets
Novartis18.11% 41.04% 14.45%
AstraZeneca 17.68%31.85%13.62%

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 1.9%. AstraZeneca pays an annual dividend of $2.17 per share and has a dividend yield of 1.2%. Novartis pays out 58.8% of its earnings in the form of a dividend. AstraZeneca pays out 30.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

AstraZeneca beats Novartis on 10 of the 18 factors compared between the two stocks.

How does Novartis compare to Novo Nordisk A/S?

Novo Nordisk A/S (NYSE:NVO) and Novartis (NYSE:NVS) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Novo Nordisk A/S has a net margin of 33.99% compared to Novartis' net margin of 18.11%. Novo Nordisk A/S's return on equity of 53.52% beat Novartis' return on equity.

Company Net Margins Return on Equity Return on Assets
Novo Nordisk A/S33.99% 53.52% 19.49%
Novartis 18.11%41.04%14.45%

Novo Nordisk A/S has higher earnings, but lower revenue than Novartis. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novo Nordisk A/S$46.80B3.97$15.51B$3.9710.48
Novartis$54.53B5.60$13.98B$5.2430.54

11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 13.1% of Novartis shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by company insiders. Comparatively, 0.0% of Novartis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Novo Nordisk A/S currently has a consensus price target of $59.44, suggesting a potential upside of 42.89%. Novartis has a consensus price target of $152.25, suggesting a potential downside of 4.86%. Given Novo Nordisk A/S's higher possible upside, research analysts clearly believe Novo Nordisk A/S is more favorable than Novartis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novo Nordisk A/S
5 Sell rating(s)
16 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.00
Novartis
3 Sell rating(s)
9 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.17

In the previous week, Novo Nordisk A/S had 13 more articles in the media than Novartis. MarketBeat recorded 33 mentions for Novo Nordisk A/S and 20 mentions for Novartis. Novartis' average media sentiment score of 0.52 beat Novo Nordisk A/S's score of 0.36 indicating that Novartis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novo Nordisk A/S
13 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
7 Negative mention(s)
5 Very Negative mention(s)
Neutral
Novartis
4 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Novo Nordisk A/S has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market. Comparatively, Novartis has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market.

Novo Nordisk A/S pays an annual dividend of $0.82 per share and has a dividend yield of 2.0%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 1.9%. Novo Nordisk A/S pays out 20.7% of its earnings in the form of a dividend. Novartis pays out 58.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Novo Nordisk A/S beats Novartis on 10 of the 18 factors compared between the two stocks.

How does Novartis compare to Pfizer?

Pfizer (NYSE:PFE) and Novartis (NYSE:NVS) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

Novartis has a net margin of 18.11% compared to Pfizer's net margin of 6.34%. Novartis' return on equity of 41.04% beat Pfizer's return on equity.

Company Net Margins Return on Equity Return on Assets
Pfizer6.34% 19.88% 8.52%
Novartis 18.11%41.04%14.45%

Pfizer presently has a consensus target price of $30.32, suggesting a potential upside of 5.12%. Novartis has a consensus target price of $152.25, suggesting a potential downside of 4.86%. Given Pfizer's stronger consensus rating and higher probable upside, analysts plainly believe Pfizer is more favorable than Novartis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pfizer
2 Sell rating(s)
14 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.18
Novartis
3 Sell rating(s)
9 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.17

68.4% of Pfizer shares are held by institutional investors. Comparatively, 13.1% of Novartis shares are held by institutional investors. 0.6% of Pfizer shares are held by insiders. Comparatively, 0.0% of Novartis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Pfizer has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, Novartis has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market.

Novartis has lower revenue, but higher earnings than Pfizer. Novartis is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pfizer$62.58B2.63$7.77B$0.7041.20
Novartis$54.53B5.60$13.98B$5.2430.54

In the previous week, Pfizer had 20 more articles in the media than Novartis. MarketBeat recorded 40 mentions for Pfizer and 20 mentions for Novartis. Novartis' average media sentiment score of 0.52 beat Pfizer's score of 0.43 indicating that Novartis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pfizer
15 Very Positive mention(s)
6 Positive mention(s)
9 Neutral mention(s)
8 Negative mention(s)
2 Very Negative mention(s)
Neutral
Novartis
4 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.0%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 1.9%. Pfizer pays out 245.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novartis pays out 58.8% of its earnings in the form of a dividend. Pfizer has increased its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Novartis beats Pfizer on 10 of the 18 factors compared between the two stocks.

Get Novartis News Delivered to You Automatically

Sign up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NVS vs. The Competition

MetricNovartisPharmaceuticals IndustryHealthcare SectorNYSE Exchange
Market Cap$305.78B$13.69B$7.84B$23.49B
Dividend Yield1.92%2.58%2.46%3.79%
P/E Ratio30.5427.2534.0825.82
Price / Sales5.607.318.533.25
Price / Cash14.9215.7421.9315.51
Price / Book8.135.144.403.66
Net Income$13.98B$2.88B$3.52B$1.08B
7 Day Performance-2.00%-3.29%-4.42%-2.50%
1 Month Performance6.24%-3.77%-3.47%-1.20%
1 Year Performance21.66%-7.21%0.15%7.34%

Novartis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NVS
Novartis
3.0654 of 5 stars
$160.02
-0.3%
$152.25
-4.9%
+22.0%$305.78B$54.53B30.5475,267
JNJ
Johnson & Johnson
3.5927 of 5 stars
$276.62
+3.9%
$275.92
-0.3%
+44.2%$665.92B$94.19B41.91138,200
MRK
Merck & Co., Inc.
4.4665 of 5 stars
$150.19
+3.8%
$155.74
+3.7%
+55.4%$370.55B$65.01B154.8475,000
AZN
AstraZeneca
4.6985 of 5 stars
$189.03
+2.8%
$206.67
+9.3%
N/A$293.17B$58.74B26.7496,100
NVO
Novo Nordisk A/S
3.9829 of 5 stars
$42.21
+5.0%
$59.44
+40.8%
-13.7%$188.45B$46.80B10.3269,505

Related Companies and Tools


This page (NYSE:NVS) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners